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Abstract: Although the pathophysiology of immunoglobulin E
(IgE)Ymediated allergic rhinoconjunctivitis and bronchial asthma is
rather well established, the role of allergy in atopic eczema (AE) is
still controversial. By a technique called atopy patch test, aeroaller-
gens like house dust mite, animal dander, or pollen were proven as
relevant trigger factors in a subgroup of patients with AE. The atopy
patch test is an epicutaneous patch test with such allergens known to
elicit IgE-mediated reactions, and used for the evaluation of
eczematous skin reactions. In a series of single-center and multicenter
studies, a method was developed, standardized, and compared with
other diagnostic techniques (radioallergosorbent test, skin prick test)
in AE patients. With regard to clinical history, the most specific
results were obtained with the atopy patch test (allergen-dependent,
69%Y92%), whereas sensitivity was higher for skin prick test (range,
69%Y82%) and specific IgE (range, 65%Y94%). The characterization
of a patient subgroup with relevant IgE-mediated allergy may lead to
more efficient avoidance and eventually even specific immunotherapy
strategies in the management of AE.
Key Words: IgE, diagnostic techniques, atopy patch test,
atopic eczema
(WAO Journal 2008;1:51Y56)
A topic eczema (AE, atopic dermatitis, AE/dermatitissyndrome) is a clinically well-defined inflammatory,
chronically relapsing, highly pruritic skin disease with a
typically age-related distribution and morphology1Y3 and a
prevalence of 2% to 10% in the population.1,4,5 Elevated
immunoglobulin E (IgE) production, especially against
aeroallergens and food allergens, and/or altered unspecific
reactivity are frequent findings in patients with AE and
concomitant respiratory atopic diseases.6,7 As a multifactorial
disease with a genetic background, AE has a large number of
individually different trigger factors.8Y11
The deterioration of AE skin lesions in some patients
after contact with certain IgE-inducing allergens like house
dust mite, pollen, or animal dander is an old clinical obser-
vation. Consequently, allergen avoidance strategies have been
used to improve the course of AE in some studies.12Y17
The inflammatory infiltrate of AE lesions consists to a
large proportion of CD4+ T helper (TH) cells. High IgE
production in patients with AE is explained by an impaired
balance of the T-cell populations TH1 and TH2, with a
predominance of interleukin-4Y and interleukin-13Yproducing
TH2 cells.
18Y23 Aeroallergens are able to penetrate the
disturbed skin barrier24 in patients with AE and were found
in direct contact with antigen-presenting Langerhans cells.25
The discovery of IgE and IgE-binding structures on the surface
of epidermal Langerhans cells26Y29 resulted in a new concept
that allergy contributes to the pathophysiology of AE because
all of the major components of an IgE-mediated reaction are
present in the epidermis. Subsequently, the function of IgE in
antigen presentation was shown by Maurer et al.30 However,
the question whether allergy plays a role in practice still
remained: measurement of specific serum IgE and skin prick
tests or intracutaneous injections of allergen solutions are
clinical routine to diagnose IgE-mediated sensitizations,6,31
but in AE, they reveal often multiple sensitizations without
clinical relevance. Furthermore, the morphology of skin test
reactions (wheal and flare) does not resemble the clinical
manifestation of AE, nor do they represent the appropriate
dimensions of the skin immune system. An additional diag-
nostic tool for aeroallergen-triggered AE was needed, and the
proof of concept study was done with a procedure our group
called atopy patch test (APT).32
Rostenberg and Sulzberger33 described in 1937 a series
of 12,000 patch tests with awide variety of allergens, including
aeroallergens in different patient groups. In 1982, Mitchell
et al34 published the first experimental patch test with
aeroallergens for patients with AE. By others, eczematous
reactions could be elicited with different methods, but the
methodology and definition of positive reactions in these trials
were not comparable.35Y45 No clear correlation with history
was obtained in larger groups of patients. Potentially irritating
procedures like stratum corneum abrasion,34,46,47 tape
stripping,48Y50 or addition of sodium laurylsulfate51 were ne-
cessary to enhance allergen penetration. In 1989, the term
atopy patch test was proposed with the following definition:
an epicutaneous patch test with allergens known to elicit IgE-
mediated reactions, and the evaluation of eczematous skin
reactions after 48 and 72 hours.32,52 The first effort was to
standardize APT and possibly develop a method for clinical
routine giving positive results only in patients with AE and
showing significant concordance to clinical relevance para-
meters of aeroallergen allergy.
METHODOLOGICAL STUDIES
Allergen lyophilisates of house dust mite Dermatopha-
goides pteronyssinus, cat dander, grass pollen, and in later
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studies, of birch and mugwort pollen were used. The test pre-
parations were developed on a noncommercial basis in coope-
ration with several industrial allergen suppliers to maintain a
high standard of batch stability and reproducibility (Hermal
and Allergopharma, Reinbek, Germany; Stallerge´nes, Antony,
France). Application in large aluminum Finn chambers (12-mm
diameter) on clinically uninvolved, nonabraded, and untreated
back skin was superior to the use of small Finn chambers.
Reproducibility of elicited APT reactions within a mean of 16
months was 94%. Vehicles were tested in control areas in all
patients and remained in general negative. At the beginning,
grading of positive APT reactions was done after 48 and 72
hours according to the International Contact Dermatitis Reseach
Group rules.53,54 Only reactions with infiltration were regarded
as clear-cut positive (example in Fig. 1). All APT studies were
performed after discontinuance of systemic antihistamines (the
effect of antihistamines on APT is not known to date) and
systemic and topical (test area) steroids for at least 7 days.
Role of the Vehicle
In a pilot study55 involving 36 patients with AE, the
reactions of 17 patients (47%) were graded as clear-cut positive.
Control sites (petrolatum, hydrogel) remained negative, non-
atopic volunteers and patients with respiratory atopy (allergic
rhinoconjunctivitis) onlywere also negative inAPT.Allergens in
petrolatumvehicle elicited twice asmany positiveAPT reactions
as the same dose in a hydrogel. Thirty-six percent of patients
reacted to house dust mite D. pteronyssinus, 22% to cat dander,
and 16% to grass pollen. A D. pteronyssinusYpositive APTwas
accompanied in 77% by a corresponding elevated specific IgE
(skin prick test, 62%).
Dose-Response Effects and Role of Localization
of Eczema
Allergen concentrations of 500, 3000, 5000, and 10,000
protein nitrogen units (PNU)/g in petrolatum were compared
in another study56 in 57 patients. The frequency of clear-cut
positive APT reactions was significantly higher in patients
with eczematous skin lesions in air-exposed areas (69%) as
compared with patients without this predictive pattern (39%;
P = 0.02). In the first group, the maximum APT reactivity was
reached at a lower allergen dose of around 5000 PNU/g.
Two hundred fifty-three adult patients with AE (Table 1)
participated in a randomized, double-blind, multicenter study
on dose-response, safety, and clinical covariates of the APT.57
The allergen dose with the most clear-cut results (positive or
negative) in adults was found for D. pteronyssinus, cat dander,
and grass pollen between 5000 and 7000 PNU/g. Most
patients reacted only to 1 allergen, rarely to 2 or 3.
Age
In 30 children and adolescents 14 years old or younger
with AE enrolled in a double-blind dose-response multicenter
study,58 a lower frequency of positive APT reactions compared
with adults was seen for D. pteronyssinus (34% vs 41% in
adults) and cat dander (12% vs 17%). ForD. pteronyssinus and
grass pollen, lower allergen doses for APT seem possible in
children because maximal response rates were obtained for
these allergens with 3000 PNU/g, half of the adult allergen
concentration.
Allergen Standardization
Comparing different allergen standardization systems in
50 patients with parallel testing, the allergen doses of 7000
PNU/g and 200 IR/g (biological unit) were found to have
similar concordance with the patients’ clinical history: 71% to
73% of APTwere corroborated by a corresponding positive or
negative history of AE flares after contact with the specific
allergen. Expressed as major allergen content, 200 IR/g
correspond to 59 Kg/mL Der p1, 9 Kg/mL Fel d1, or 2 Kg/mL
Phl p1.
In summary, these studies showed that:
& a safe standardized APT method with positive reactions only
in patients with AE was developed;
& allergen lyophilisate in petrolatum is the preferred galenic
preparation;
& APT is possible on nonabraded skin without manipulation
of the skin barrier function;
& allergen concentrations higher than in most prick test solu-
tions are necessary for APT, but lower doses can be used in
children;
& D. pteronyssinus is the most frequent allergen eliciting
positive APT reactions, with reactions to pollen allergens
also being very frequent; and
& high allergen-specific IgE in serum is not a prerequisite for a
positive APT.
APT AND SPECIFIC IgE
The percentages of positive reactions in different test
systems for IgE-mediated hypersensitivity obtained from our
multicenter studies are given in Table 1. These and previous
APT studies showed that positive APT occurred less
frequently than positive skin prick tests or radioallergosorbent
tests (RASTs) to the same allergen. Logistic regression
analysis57 revealed patient’s history, skin prick test, and
specific corresponding IgE for D. pteronyssinus, cat dander,
and grass pollen as most important significant predictors of a
positive APT (P G 0.001). However, the cross-tabulation also
confirmed that high allergen-specific IgE in serum is not
mandatory for a positive APT (example in Table 2), the same
holds true for the correlation with skin prick tests. A European
FIGURE 1. The APT with house dust mite D. pteronyssinus
in a patient with AE. Eczematous reaction after 48 hours.
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multicenter study59 on standardized APT in 6 countries (n =
314) showed a subgroup of 7% APT-positive AE patients
without any positive skin prick test or elevated specific IgE in
the investigated allergen panel (Fig. 2). Nevertheless, these
reactions can be of clinical relevance and immunological
specificity.60 In conclusion,
& the APT may give further diagnostic information in addition
to patient’s history and classical tests of IgE-mediated
hypersensitivity;
& the role for IgE in the reaction mechanism of APT is
corroborated because in most APT-positive patients, ele-
vated specific IgE was found compared with those with
negative APT; and
& a cellular mechanism without direct involvement of IgE may
be hypothesized to explain the clear-cut positive APT
reactions in a subgroup of AE patients.
IgE-MEDIATED SENSITIZATION AND APT:
DIAGNOSTIC PRECISION
Unlike in food allergic patients, a Bgolden standard[ of
provocation of aeroallergen-induced AE is not established.
The prospectively obtained history of allergen-induced
exacerbations of AE, especially in a seasonal allergen, can
be used to evaluate the clinical relevance of an APT result like
in conventional patch testing. Rajka3 reported on the
phenomenon of Bsummer eruption,[ that is, eczema flares
during spring and summer, the pollen seasons of birch and
grass, in one third of patients with AE. According to our
results, one third of patients with specific IgE to grass pollen
can have a positive APT reaction to this allergen.57 In a study
on the influence of grass pollen on AE,61 we tested 79 patients
with an APTwith 10,000 PNU/g grass pollen allergen mixture
in petrolatum and simultaneously with 10 mg of dry
unprocessed grass pollen of Dactylis glomerata. Significantly
higher frequencies of positive APT occurred in patients with a
history of exacerbation of AE in the summer months of the
previous year or in direct contact with grass (n = 12, 75% had
positive APT) compared with patients without this history (n =
67, 16% had positive APT; P G 0.001). Sensitivity and
specificity of APT and classical tests for IgE-mediated
sensitization are given in Table 3. The standardized APT
also correlated with a predictive eczema pattern, skin prick
test, and specific IgE to grass pollen (P G 0.01). Moreover,
unprocessed grass pollen also elicited eczematous skin
reactions on nonpretreated skin of patients with AE, sig-
nificantly associated to history and a positive standardized
APT with lyophilisate. Again, in healthy and rhinoconjuncti-
vitis controls, no positive reactions were observed.
In a larger patient group in the German multicenter
study,57 APT results of D. pteronyssinus, cat dander, and grass
pollen were also statistically significantly associated with
clinical history (P G 0.001, W2 and logistic regression; birch
pollen, P = 0.1). Thus, sensitivity and specificity of different
diagnostic tests could be compared. Allergen-dependent, the
APT showed a higher specificity with regard to clinical
relevance of an allergen than skin prick test and specific IgE,
but also in most allergens, a lower sensitivity (Table 3). In a
subgroup of these patients, specific activation and proliferation
of T cells in peripheral blood was compared with the patient’s
APT result.62 Positive APT reactions were significantly more
frequent in patients with elevated CD54+ or CD30+ T cells after
in vitro stimulation with the corresponding allergen. In
addition, positive APT results were associated with an
allergen-specific lymphocyte proliferation (P G 0.001). Positive
APT reactions were not associated with disease severity in the
SCORAD (scoring atopic dermatitis) system.62,63
TABLE 2. Cross-Tabulation of APT and Specific IgE to House
Dust Mite D. pteronyssinus, Results of a Multicenter Study57
APT 48-h Results in Adult Patients for House





APT negative 49 29 78
APT positive 13 60 73
Total 62 89 151
FIGURE 2. In 53 (17%) of 314 patients of a European
multicenter study,59 positive APT reactions, but negative
corresponding skin prick test/specific IgE results, were observed
(1 allergen, n = 26; 2 allergens, n = 12). In 22 of these
patients with a clear-cut positive APT result, no positive skin
prick test or elevated specific serum IgE of the investigated
allergen panel was seen (7% of total). The figure shows that
all allergens contribute to these reactions.
TABLE 1. Clinical Covariates of the APT in 2 Multicenter Studies With Different Allergen Standardization
Skin Prick sIgE APT History
A B A B A B A B
D. pteronyssinus 59 56 56 56 34 39 52 34
Cat dander 54 44 49 46 12 10 23 30
Grass pollen 65 57 75 59 18 15 33 31
Birch pollen 65 49 65 53 11 17 13 20
A indicates German multicenter57 (7 centers, N = 253 adults, 3000Y10,000 PNU/g); B, European multicenter59 (6 countries, 12 centers, N = 314, 200 IR/g).
Values are expressed as percentages.
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From APT biopsies, allergen-specific T cells have
been cloned. In serial biopsies, T cells showed a character-
istic TH2 secretion pattern (interleukin-4, -13) at 24 hours,
whereas after 48 hours, a TH1 pattern (interferon-F) like in
chronic AE lesions was predominant.64Y66 Taken together,
these findings:
& argue against the interpretation of APT results as irritative or
nonspecific;
& suggest that pollen are involved in AE flares in some
patients previously diagnosed as having UV-triggered
eczema;
& demonstrate the clinical relevance of positive APT reactions
and the different compartments of allergic inflammation that
can be investigated with skin prick test, specific serum IgE
determination, and APT;
& show that allergen-specific T cells and IgE play a role in the
pathophysiology of APT reactions; and
& sustain the concept that AE is not only a disease of dry skin
or barrier dysfunction, but also an allergic disease.
THE FUTURE OF THE APT
Appropriate allergen-specific avoidance strate-
gies13,14,16,67,68 are recommended in patients showing positive
APT reactions. The identified subgroup of patients may profit
extraordinarily from allergen avoidance, but controlled studies
using specific provocation and elimination procedures in
patients with positive and negative APT results are still
necessary. Standardization of major allergen content and
achieving an increase in the sensitivity of APT are important
goals of ongoing trials. The combination of APT and specific
IgE results may lead to higher diagnostic precision, but the
problem of discordant tests has to be solved. Meetings of most
European groups performing APT for clinical use in 1997,
1998, and 2003 resulted in a consensus APT reading key of the
European Task Force on Atopic Dermatitis (Fig. 3).60,69 The
European multicenter trial also started the investigation of
food allergen patch testing with lyophilisates in petrolatum.
The development of a standardized APT for food allergy is a
future plan, as well as a study on the mechanisms of APT
reactions involving both patients with intrinsic and extrinsic
AE and investigating the role of the Fc? receptor I and
allergen-specific T-cell populations. Furthermore, the APTwill
be used in trials on topical and systemic therapy for AE and is
evaluated as itch model.70,71 Other aeroallergens of regional
significance are to be standardized. A test for the clinical
relevance of an aeroallergen sensitization that can be applied
in the allergist’s practice may evolve soon. The APT may also
be valuable in selecting patients for specific immunotherapy.
To solve the remaining tasks in due time and to overcome the
methodological inconsistencies of different groups, the
organization of international multicenter studies is necessary.
A recent European Academy of Allergology and Clinical
Immunology/Global Allergy and Asthma European Network
position paper focused on clinical results and unresolved
problems of APT.72
CONCLUDING REMARKS
The described APT methodology was evaluated in
several hundreds of patients with AE. In a large subgroup of
them, IgE-dependent allergic reactions that are elicited by the
transdermal route play a pathophysiological role. For patients
with aeroallergen-triggered disease, the APT may provide an
important diagnostic tool, a provocation test of the skin in
analogy to the specific provocation methods in respiratory
atopy. As in respiratory atopy, the results of our studies sustain
B. Wu¨thrich’s concept of extrinsic/allergic versus intrinsic/
idiopathic AE.73
Positive APT results were obtained in some AE patients
with negative skin prick tests and RAST, but predictive
history. According to the previously mentioned concept, these
cases may also be classified as Bextrinsic,[ and with the back-
ground of the recently proposed novel nomenclature for
allergy,74 we suggested to diagnose these cases as Bnon-
IgEYassociated AE (dermatitis syndrome).[60
TABLE 3. Sensitivity and Specificity of Different Diagnostic
Methods in 2 Studies With Patients With AE
Test Sensitivity* Specificity*
Single-center study, n = 79 (allergen, grass pollen)
Skin prick 100 33
RAST 92 33
APT 75 84
APT multicenter study, n = 253 (3 allergens)
Skin prick 69Y82 44Y53
RAST 65Y94 42Y64
APT 42Y56 69Y92
Better results are obtained with a seasonal allergen. Data from Ref. 61 and Ref. 57
*Referring to predictive history of eczema exacerbations in pollen season or in direct
contact with allergen, excluding questionable cases, depending on allergen.
Values are expressed as percentages.
FIGURE 3. The APT reaction grading key (2003 European
Task Force on Atopic Dermatitis consensus).
Darsow and Ring WAO Journal & Volume 1, Number 3, March 2008
54 * 2008 World Allergy Organization
ACKNOWLEDGMENTS
This work was only possible with the significant
contributions of the collaborators and coauthors of the cited
studies.
REFERENCES
1. Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm
Venereol. 1980;114:146Y148.
2. Jones HE, Inouye JC, McGerity JL, Lewis CW. Atopic disease and serum
immunoglobulin-E. Br J Dermatol. 1975;92:17Y25.
3. Rajka G. Essential Aspects of Atopic Dermatitis. Berlin: Springer, 1989.
4. Hanifin JM. Clinical and basic aspects of atopic dermatitis. Semin
Dermatol. 1983;2:5.
5. Leung DYM, Rhodes AR, Geha RS, Schneider LC, Ring J. Atopic
dermatitis (atopic eczema). In: Fitzpatrick TB, Eisen AZ, Wolff K,
Freedberg IM, Austen KF, eds. Dermatology in General Medicine, 4th ed.
New York: McGraw Hill, 1993:1543Y1563.
6. Ring J. Angewandte Allergologie, 3. Aufl. Mu¨nchen: MMV Medizin
Verlag; 2004.
7. Ring J. Atopy: condition, disease, or syndrome? In: Ruzicka T, Ring J,
Przybilla B, eds. Handbook of Atopic Eczema. 2nd ed. Berlin, Germany:
Springer; 2006:3Y9.
8. Morren MA, Przybilla B, Bamelis M, et al. Atopic dermatitis: triggering
factors. J Am Acad Dermatol. 1994;31:467Y473.
9. Przybilla B, Ring J. Food allergy and atopic eczema. Semin Dermatol.
1990;9:220Y225.
10. Skov L, Baadsgaard O. Ultraviolet BYexposed major histocompatibility
complex class II positive keratinocytes and antigen-presenting cells
demonstrate a differential capacity to activate T cells in the presence
of staphylococcal superantigens. Br J Dermatol. 1996;134:824Y830.
11. van Bever HP, Docx M, Stevens WJ. Food and food additives in severe
atopic dermatitis. Allergy. 1989;44:588Y594.
12. Barnetson RSTC, MacFarlane HAF, Benton EC. House dust mite allergy
and atopic eczema: a case report. Br J Dermatol. 1987;116:857Y860.
13. Fukuda H, Imayama S, Okada T. Mite-free room (MFR) for the
management of atopic dermatitis. Jpn J Allergol. 1991;40:626Y632.
14. Ring J, Brockow K, Abeck D. The therapeutic concept of Bpatient
management[ in atopic eczema. Allergy. 1996;51:206Y215.
15. Sanda T, Yasue T, Oohashi M, Yasue A. Effectiveness of house dust-mite
allergen avoidance with atopic dermatitis. J Allergy Clin Immunol.
1992;89:653Y657.
16. Tan B, Weald D, Strickland I, Friedman P. Double-blind controlled trial
of effect of housedust-mite allergen avoidance on atopic dermatitis.
Lancet. 1996;347:15Y18.
17. Tupker R, DeMonchy J, Coenraads P, Homan A, van der Meer J. Induction
of atopic dermatitis by inhalation of house dust mite. J Allergy Clin
Immunol. 1996;97:1064Y1070.
18. Grewe M, Gyufko K, Scho¨pf E, Krutmann J. Lesional expression
of interferon-gamma in atopic eczema. Lancet. 1994;I:25Y26.
19. Leung DYM, Ghan AK, Schneeberger EE, Geha RS. Characterization
of the mononuclear cell infiltrate in atopic dermatitis using mononuclear
antibodies. J Allergy Clin Immunol. 1983;71:47Y56.
20. Ohmen JD, Hanifin JM, Nickoloff BJ, et al. Overexpression of IL-10
in atopic dermatitis. Contrasting cytokine patterns with delayed-type
hypersensitivity reactions. J Immunol. 1995;154:1956Y1963.
21. Renz H, Jujo K, Bradley K, et al. Enhanced IL-4 production and IL-4
receptor expression in atopic dermatitis and their modulation by
interferon-gamma. J Invest Dermatol. 1992;99:403Y408.
22. Sowden J, Powell R, Allen B. Selective activation of circulating CD4+
lymphocytes in severe adult atopic dermatitis. Br J Dermatol. 1992;
127:228Y232.
23. Vercelli D, Jabara H, Lauener R, Geha R. IL-4 inhibits the synthesis
of INF-gamma and induces the synthesis of IgE in human mixed
lymphocyte cultures. J Immunol. 1990;144:570Y573.
24. Scha¨fer L, Kragballe K. Abnormalities in epidermal lipid metabolism
in patients with atopic dermatitis. J Invest Dermatol. 1991;96:10Y15.
25. Maeda K, Yamamoto K, Tanaka Y, Anan S, Yoshida H. House dust mite
(HDM) antigen in naturally occurring lesions of atopic dermatitis (AD):
the relationship between HDM antigen in the skin and HDM
antigen-specific IgE antibody. J Dermatol Sci. 1992;3:73Y77.
26. Bieber T, de la Salle C, Wollenberg A, Hakimi J, Chizzonite R, Ring J.
Constitutive expression of the high affinity receptor for IgE (FCeR1)
on human Langerhans-cells. J Exp Med. 1992;175:1285Y1290.
27. Bieber T, Rieger A, Neuchrist C, et al. Induction of FCeR2/CD23 on
human epidermal Langerhans cells by human recombinant IL4 and IFN.
J Exp Med. 1989;170:309Y314.
28. Bieber T. FCeRI on human Langerhans cells: a receptor in seach
of new functions. Immunol Today. 1994;15:52Y53.
29. Bruijnzeel-Koomen C, van Wichen DF, Toonstra J, Berrens L, Bruijnzeel
PLB. The presence of IgE molecules on epidermal Langerhans cells
in patients with atopic dermatitis. Arch Dermatol Res. 1986;278:
199Y205.
30. Maurer D, Ebner C, Reininger B, Fiebiger E, Kraft D, Kinet Jp, Stingl G.
The high affinity IgE receptor mediates IgE-dependent allergen
presentation. J Immunol. 1995;154:6285Y6290.
31. Darsow U. Etablierte Diagnostikverfahren. In: Ring J, ed. Neurodermitis.
Landsberg: Ecomed, 1998:61Y73.
32. Ring J, Kunz B, Bieber T, Vieluf D, Przybilla B. The Batopy patch test[
with aeroallergens in atopic eczema. J Allergy Clin Immunol. 1989;82:
195. [abstract].
33. Rostenberg A, Sulzberger MD. Some results of patch tests. Arch Dermatol.
1937;35:433Y454.
34. Mitchell E, Chapman M, Pope F, Crow J, Jouhal S, Platts-Mills T.
Basophils in allergen-induced patch test sites in atopic dermatitis.
Lancet. 1982;I:127Y130.
35. Adinoff A, Tellez P, Clark R. Atopic dermatitis and aeroallergen
contact sensitivity. J Allergy Clin Immunol. 1988;81:736Y742.
36. Clark R, Adinoff A. Aeroallergen contact can exacerbate atopic
dermatitis: patch test as a diagnostic tool. J Am Acad Dermatol.
1989;21:863Y869.
37. Imayama S, Hashizuma T, Miyahara H, et al. Combination of patch
test and IgE for dust mite antigens differentiates 130 patients with
atopic dermatitis into four groups. J Am Acad Dermatol. 1992;27:
531Y538.
38. Platts-Mills T, Mitchell E, Rowntree S, Chapman M, Wilkins S.
The role of dust mite allergens in atopic dermatitis. Clin Exp Dermatol.
1983;8:233Y247.
39. Reitamo S, Visa K, Kaehoenen K, Ka¨ykho¨ A, Lauerna I, Stubb S,
Salo OP. Patch test reactions to inhalant allergens in atopic dermatitis.
Acta Derm Venereol. 1989;144:119Y121.
40. Reitamo S, Visa K, Ka¨ho¨nen K, Stubb S, Salo OP. Eczematous
reactions in atopic patients caused by epicutaneous testing with inhalant
allergens. Br J Dermatol. 1986;114:303Y309.
41. Seidenari S, Manzini BM, Danese P, Giannetti A. Positive patch tests
to whole mite culture and purified mite extracts in patients with
atopic dermatitis, asthma and rhinitis. Ann Allergy. 1992;69:201Y206.
42. Seidenari S, Manzini M, Danese P. Patch testing with pollens of
Gramineae in patients with atopic dermatitis and mucosal atopy.
Contact Dermatitis. 1992;27:125Y126.
43. Seifert H, Wollemann G, Seifert B, Borelli S. Neurodermitis:
Eine Protein-Kontaktdermatitis? Dtsch Derm. 1987;35:1204Y1214.
44. Vieluf D, Kunz B, Bieber T, Przybilla B, Ring J. Atopy patch test
with aeroallergens in patients with atopic eczema. Allergo J. 1993;
2:9Y12.
45. Vocks E, Seifert H, Seifert B, Drosner M. Patch test with immediate
type allergens in patients with atopic dermatitis. In: Ring J, Przybilla B,
eds. New Trends in Allergy III. Berlin: Springer; 1991:230Y233.
46. Gondo A, Saeki N, Tokuda Y. Challenge reactions in atopic dermatitis
after percutaneous entry of mite antigen. Br J Dermatol. 1986;115:
485Y493.
47. Norris P, Schofield O, Camp R. A study of the role of house dust mite
in atopic dermatitis. Br J Dermatol. 1988;118:435Y440.
48. Bruijnzeel-Koomen C, van Wichen D, Spry C, Venge P, Bruynzeel P.
Active participation of eosinophils in patch test reactions to inhalant
allergens in patients with atopic dermatitis. Br J Dermatol. 1988;
118:229Y238.
49. Langeland T, Braathen L, Borch M. Studies of atopic patch tests.
Acta Derm Venereol. 1989;144:105Y109.
50. van Voorst Vader PC, Lier JG, Woest TE, Coenraads PJ, Nater JP.
Patch tests with house dust mite antigens in atopic dermatitis patients:
methodological problems. Acta Derm Venereol. 1991;71:301Y305.
51. Tanaka Y, Anan S, Yoshida H. Immunohistochemical studies in mite
WAO Journal & Volume 1, Number 3, March 2008 Role of IgE-Mediated Allergy in Atopic Eczema
* 2008 World Allergy Organization 55
antigen-induced patch test sites in atopic dermatitis. J Dermatol Sci.
1990;1:361Y368.
52. Ring J, Bieber T, Vieluf D, Kunz B, Przybilla B. Atopic eczema,
Langerhans cells and allergy. Int Arch Allergy Appl Immunol.
1991;94:194Y201.
53. Andersen KE, et al, The European Environmental and Contact Dermatitis
Research Group. Contact dermatitis: a review. Contact Dermatitis.
1987;16:55Y78.
54. Fisher AA. Contact Dermatitis, 3rd ed. Philadelphia: Lea & Febiger,
1986:686Y691.
55. Darsow U, Vieluf D, Ring J. Atopy patch test with different vehicles
and allergen concentrationsVan approach to standardization. J Allergy
Clin Immunol. 1995;95:677Y684.
56. Darsow U, Vieluf D, Ring J. The atopy patch test: an increased rate of
reactivity in patients who have an air-exposed pattern of atopic eczema.
Br J Dermatol. 1996;135:182Y186.
57. Darsow U, Vieluf D, Ring J, for the APT study group. Evaluating the
relevance of aeroallergen sensitization in atopic eczema using the tool
Batopy patch test[: a randomized, double-blind multicenter study.
J Am Acad Dermatol. 1999;40:187Y193.
58. Darsow U, Vieluf D, Berg B, et al. Dose response study of atopy patch test
in children with atopic eczema. Pediatr Asthma Allergy Immunol. 1999;
13:115Y122.
59. Darsow U, Laifaoui J, Bolhaar S, et al. The prevalence of positive
reactions in the atopy patch test with aeroallergens and food allergens
in subjects with atopic eczema: a European multicenter study.
Allergy. 2004;59:1318Y1325.
60. Kerschenlohr K, Gu¨nther S, Darsow U, Ollert M, Wollenberg A.
Clinical and immunological reactivity to aeroallergens in Bintrinsic[
atopic dermatitis patients. J Allergy Clin Immunol. 2003;111:195Y197.
61. Darsow U, Behrendt H, Ring J. Gramineae pollen as trigger factors
of atopic eczema: evaluation of diagnostic measures using the atopy
patch test. Br J Dermatol. 1997;137:201Y207.
62. Wistokat-Wu¨lfing A, Schmidt P, Darsow U, Ring J, Kapp A, Werfel T.
Atopy patch test reactions are associated with T lymphocyteYmediated
allergen-specific immune responses in atopic dermatitis. Clin Exp Allergy.
1999;29:513Y521.
63. European Task Force on Atopic Dermatitis. Severity scoring of atopic
dermatitis: the SCORAD index. Dermatology. 1993;186:23Y31.
64. Ramb-Lindhauer CH, Feldmann A, Rotte M, Neumann CH.
Characterization of grass pollen reactive T-cell lines derived from lesional
atopic skin. Arch Dermatol Res. 1991;283:71Y76.
65. Sager N, Feldmann A, Schilling G, Kreitsch P, Neumann C.
House dust miteYspecific T cells in the skin of subjects with atopic
dermatitis: frequency and lymphokine profile in the allergen patch test.
J Allergy Clin Immunol. 1992;89:801Y810.
66. van Reijsen FC, Bruynzeel-Koomen CAFM, Kalthoff FS, Maggi E,
Romagnani S, Westland JKT, Mudde GC. Skin-derived
aeroallergen-specific T-cell clones of TH2 phenotype in patiens with
atopic dermatitis. J Allergy Clin Immunol. 1992;90:184Y192.
67. Weissenbacher S, Bacon T, Targett D, Behrendt H, Ring J, Darsow U.
Atopy patch testVreproducibility and elicitation of itch in different
application sites. Acta Derm Venereol. 2005;85:147Y151.
68. Lau S, Ehnert B, Cremer B, Nasert S, Bu¨ttner P, Czarnetzki BM,
Wahn U. Ha¨usliche Milbenallergenreduktion bei spezifisch
sensibilisierten Patienten mit atopischem Ekzem. Allergo J. 1995;4:
432Y435.
69. Darsow U, Ring J. Airborne and dietary allergens in atopic eczema:
a comprehensive review of diagnostic tests. Clin Exp Dermatol. 2000;
25:544Y551.
70. Weissenbacher S, Bacon T, Targett D, Behrendt H, Ring J, Darsow U.
Atopy patch testVreproducibility and elicitation of itch in different
application sites. Acta Derm Venereol. 2005;85:147Y151.
71. Weissenbacher S, Traidl-Hoffmann C, Eyerich K, et al. Modulation
of atopy patch test and skin prick test by pretreatment with 1%
pimecrolimus cream. Int Arch Allergy Immunol. 2006;140:
239Y244.
72. Turjanmaa K, Darsow U, Niggemann B, Rance´ F, Vanto T, Werfel T.
EAACI/GA2LEN Position Paper: present status of the atopy patch
testVposition paper of the Section on Dermatology and the Section
on Pediatrics of the EAACI. Allergy. 2006;61:1377Y1384.
73. Wu¨thrich B. Neurodermitis atopica sive constitutionalis. Ein
pathogenetisches Modell aus der Sicht des Allergologen.
Akt Dermatol. 1983;9:1Y7.
74. Johansson SGO, Bieber T, Dahl R, et al. Revised nomenclature for allergy
for global use: report of the Nomenclature Review Committee of the
World Allergy Organization, October 2003. J Allergy Clin Immunol.
2004;113:832Y836.
Darsow and Ring WAO Journal & Volume 1, Number 3, March 2008
56 * 2008 World Allergy Organization
